12 research outputs found
Additional file 1 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
Additional file 1: Table S1. Eligibility criteria for the DIANA study
Additional file 2 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
Additional file 2: Fig. S1. Doses of dotinurad at each visit
Additional file 4 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
Additional file 4: Table S3. Odds ratios for achieving an SUA level of ≤ 6.0 mg/dL according to baseline SUA levels
Additional file 7 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
Additional file 7: Text S1. DIANA Study Organization and Investigators
Additional file 6 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
Additional file 6: Table S5. Associations between changes in SUA and parameters of interest at week 24
Additional file 3 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
Additional file 3: Table S2. SUA raw data at baseline and at weeks 4, 8, 12, and 24
Additional file 5 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
Additional file 5: Table S4. Estimated changes in blood pressures and laboratory biomarkers over 24Â weeks
By-Laws of the Cooperative
Additional file 3.  Routine blood and urine examination
MOESM1 of Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study
Additional file 1. Trial organization